Regulatory requirements for GLP labs

September 3, 2025

Introduction to GLP Compliance

Good Laboratory Practice (GLP) sets the groundwork for generating reliable and credible safety data crucial for regulatory submissions. Initiated in response to substandard practices observed in the 1970s, GLP regulations have evolved to ensure transparency, integrity, and accountability in non-clinical laboratory testing. Pertinent regulatory bodies like the FDA and EPA enforce these standards, making compliance a non-negotiable aspect for laboratories worldwide.

Understanding Good Laboratory Practice (GLP)

What is Good Laboratory Practice (GLP)?

Good Laboratory Practice (GLP) is a rigorous system of principles designed to assure the quality, integrity, and reliability of non-clinical laboratory studies, particularly in health and environmental safety sectors. The GLP framework lays out how studies should be planned, executed, monitored, documented, reported, and archived. This structured approach is crucial for generating trustworthy data, especially in fields that significantly impact public health, such as pharmaceutical and chemical testing.

Significance of GLP in Regulatory Processes

GLP regulations establish minimum requirements for laboratories that conduct studies supporting applications for products regulated by authorities such as the FDA and EPA. Compliance with GLP is vital for ensuring that the data submitted for drug approval or pesticide registration is credible and can be independently verified. It aims to protect human subjects during drug development by enforcing high standards in study design and execution. Regulatory bodies rely on GLP-validated safety data to make informed decisions regarding product approvals, as detailed GLP documentation provides transparency and accountability.

Coordination and Compliance in the EU

In the European Union, GLP compliance adheres to laws provided under Directive 2004/9/EC and Directive 2004/10/EC, which require member states to designate GLP inspection authorities. The European Medicines Agency (EMA) plays a crucial role in overseeing and coordinating GLP inspections, ensuring that laboratories across the EU consistently meet established GLP standards. These regulatory frameworks not only enhance data reliability but also streamline interactions between laboratories and regulatory bodies, optimizing the approval process for new medicines and ensuring that public safety remains a priority.

Importance of GLP Compliance

Why is compliance with GLP important?

Compliance with Good Laboratory Practice (GLP) is crucial as it ensures that non-clinical safety data is dependable and replicable. These data are essential for regulatory submissions across a variety of sectors, including pharmaceuticals, agrochemicals, and cosmetics. Regulatory agencies like the FDA and EPA mandate adherence to GLP standards to maintain the integrity of the data they rely on for safety evaluations.

In the UK, for instance, the GLP compliance monitoring programme, overseen by the UK GLP Monitoring Authority, conducts regular inspections on facilities necessitating strict adherence. Deficiencies uncovered during these inspections can lead to serious repercussions—issues are classified into critical and major levels, highlighting the vital need for rigid compliance with GLP regulations.

Role of regulatory bodies in GLP oversight

Regulatory bodies are pivotal in overseeing GLP compliance. Their inspections help to verify that laboratories follow established procedures. The FDA and EPA enforce regulations that require GLP compliance, which includes thorough audits of facilities, equipment, and safety data. This scrutiny helps in safeguarding public health by ensuring that the studies validating product safety are robust and conducted under widely accepted standards.

Standards and inspections

The GLP framework encompasses a set of defined standards that laboratories must meet, including training personnel and maintaining thorough documentation. Inspections are a key element of monitoring compliance, including internal checks and external reviews by regulatory authorities. These inspections ensure that all processes, from data recording to operational protocols, align with the principles of GLP, thereby maintaining high research quality and credibility.

An Overview of 21 CFR Part 58

Can you explain the specific regulations contained in 21 CFR Part 58 regarding GLP?

21 CFR Part 58 outlines crucial Good Laboratory Practice (GLP) regulations designed to guarantee the integrity and quality of nonclinical laboratory studies supporting applications for products regulated by the FDA. This includes a variety of items such as food additives, pharmaceuticals, and medical devices.

Scope and Structure of 21 CFR Part 58

The regulation is structured into several subparts:

  • Subpart A : General provisions and definitions.
  • Subpart B : Organizational and personnel requirements, defining roles such as the Study Director and Quality Assurance Unit (QAU).
  • Subpart C : Facility requirements that ensure proper conditions for conducting studies.
  • Subpart D : Equipment standards necessary for accurate data generation.
  • Subparts F and G : Guidelines for handling test and control articles and study conduct protocols.
  • Subpart J : Mandates the maintenance of accurate records and comprehensive reporting from studies.
  • Subpart K : Outlines disqualification grounds for testing facilities regarding compliance failures.

Roles Defined Under the Regulation

Key personnel are defined, including:

  • Study Director : Oversees compliance with GLP and manages protocol execution.
  • Quality Assurance Unit (QAU) : Independent monitor ensuring adherence to GLP throughout the study process.

Specific Procedural Guidelines

The procedural guidelines emphasize employing qualified personnel, maintaining Standard Operating Procedures (SOPs), and ensuring proper documentation of all studies. This systematic approach is fundamental to validating the safety data required for FDA submissions, enhancing reliability and accountability in laboratory practices.

In summary, 21 CFR Part 58 provides a comprehensive framework essential for conducting quality nonclinical laboratory studies conforming to regulatory standards.

Essential Principles and Components of GLP

What are the general requirements for GLP compliance?

Good Laboratory Practice (GLP) is governed by a set of essential principles designed to ensure the integrity and quality of nonclinical laboratory studies. The general requirements for GLP compliance cover several key areas:

  • Organizational Structure : A robust management system must be established, detailing the responsibilities of personnel, including a designated Study Director.

  • Quality Assurance Program : An independent Quality Assurance Unit (QAU) should be present to monitor adherence to GLP principles and conduct inspections throughout the study.

  • Qualified Personnel : All staff involved in GLP studies must possess appropriate education and training, with documentation maintained to verify their qualifications.

  • Standard Operating Procedures (SOPs) : SOPs must be documented and followed for consistency in research practices and to maintain quality control.

  • Documentation and Record Keeping : Detailed records for test substances, methodologies, deviations, and results must be meticulously maintained, ensuring accountability and traceability throughout the study. Records are generally retained for at least five years.

  • Data Integrity : The Study Director is responsible for ensuring that all activities comply with GLP standards and that the data generated meet quality requirements.

Effective implementation of these components helps to safeguard the reliability of nonclinical studies and the safety of resulting products.

Responsibilities of personnel

Personnel involved in GLP studies play crucial roles in maintaining compliance. The Study Director oversees the entire process, ensuring that all GLP regulations are met. The responsibilities include:

  • Supervision of Study Execution : Directing the study by ensuring that all protocols are followed as per GLP regulations.

  • Training and Qualification Management : Ensuring that all personnel have the necessary training and expertise to perform their tasks within GLP frameworks.

  • Quality Assurance Oversight : Collaborating with the QAU to facilitate regular inspections and reporting on compliance and deviations.

  • Record Maintenance : Ensuring that all documentation is accurate, legible, and stored according to GLP standards for future reference and auditing purposes.

By adhering to these responsibilities, laboratory staff contribute significantly to the overall quality and integrity of nonclinical studies, which is imperative for regulatory submissions.

Comparing GLP with GMP

How does GLP differ from Good Manufacturing Practices (GMP)?

GLP (Good Laboratory Practice) and GMP (Good Manufacturing Practices) serve distinct, yet complementary, roles in the pharmaceutical and healthcare industries.

Focus Areas

  • GLP : Primarily concerned with the quality and integrity of nonclinical laboratory safety studies. It ensures that these studies are conducted and documented reliably for regulatory review, particularly for research and marketing applications.
  • GMP : Concentrates on the manufacturing processes, ensuring that pharmaceutical and healthcare products are consistently produced to meet predefined quality criteria.

Roles in Drug Development Lifecycle

In terms of the drug development lifecycle, the two practices operate at different stages.

  • GLP Phase : Precedes clinical trials. It lays the groundwork by validating the safety and efficacy of substances through rigorous nonclinical studies.
  • GMP Phase : Comes into play during the manufacturing stage, ensuring that products manufactured for human use meet the required safety and effectiveness standards.

Quality Assurance Frameworks

Both GLP and GMP have established quality assurance frameworks, though their structures differ.

  • GLP : Utilizes a Study Director to oversee studies and a Quality Assurance Unit (QAU) for compliance and audit functions.
  • GMP : Implements a Quality Control Unit that oversees the entire manufacturing process.

In summary, while GLP focuses on pre-manufacture research integrity and documentation, GMP ensures product quality during production, with specific quality assurance roles tailored to their respective areas. This distinction is essential for protecting public health and maintaining high standards throughout drug development and manufacturing.

International and US Legal Requirements for GLP

Is GLP a legal requirement internationally and in the US?

Yes, Good Laboratory Practice (GLP) is a legal requirement internationally and specifically in the US for test facilities conducting regulatory studies on various products, including pharmaceuticals, agrochemicals, and cosmetics. Compliance with GLP ensures studies are accepted by regulatory authorities, highlighting its critical role in research reliability.

In the United States, the FDA oversees GLP adherence as outlined in 21 CFR Part 58, which mandates stringent standards for nonclinical laboratory studies. The EPA also enforces GLP requirements for studies supporting pesticide safety and efficacy.

In the UK, the UK GLP Monitoring Authority (UK GLPMA) manages compliance monitoring programs. This includes regular inspections and audits, typically conducted every 12 to 30 months. Facilities must retain study reports and raw data for a minimum of 2 years to demonstrate compliance and accountability.

Monitoring programs for GLP compliance

Monitoring programs for GLP compliance are essential for ensuring that laboratories adhere to established quality standards. The OECD has developed principles to unify GLP compliance across member countries, leading to mutual acceptance of data generated under these practices. Evaluating adherence involves both internal audits and external inspections conducted by designated authorities, which verify that facilities meet GLP regulations.

Enforcement and inspections

Enforcement of GLP regulations necessitates rigorous inspections, with agencies like the FDA and EPA playing pivotal roles. These inspections focus on various aspects, such as the quality assurance unit's functions, staff credentials, and the integrity of study data. Noncompliance could result in penalties, including suspension or revocation of GLP status, reinforcing the importance of strict adherence to GLP standards across laboratories.

Requisites for GLP-Compliant Facilities

What are the critical facility requirements for a GLP-compliant laboratory?

To achieve compliance with Good Laboratory Practice (GLP) regulations, a laboratory must be specifically designed to safeguard the integrity of studies. Key facility requirements include:

  • Designated Areas : There must be clearly defined spaces for receiving, storing, and mixing test and control articles. This design is crucial to prevent cross-contamination among different test materials, which could compromise study results.
  • Quality Assurance Unit (QAU) : It is mandatory to have an independent QAU that regularly inspects and monitors adherence to GLP standards, ensuring that all aspects of the study are compliant.
  • Well-Maintained Equipment : Lab equipment must not only be adequately designed but also maintained and calibrated on a routine basis to guarantee accurate and reliable data collection.
  • Documentation Practices : Thorough record retention practices, including logging all experiments and maintaining data integrity, are paramount. This involves systematic documentation of procedures, raw data, and results to allow for traceability and review.
  • Study Protocol Oversight : Appointing a qualified study director is essential. The study director oversees the entire research process and ensures compliance with the planned methodologies and protocols.

Lastly, adherence to the ten principles of GLP, which encompass areas like organization, personnel, and quality assurance programs, solidifies the guarantee that all studies conducted within the facility meet regulatory expectations.

Conclusion and Future Outlook

GLP regulations provide a solid foundation for the integrity and reliability of nonclinical studies. As scientific advancements continue, so too will the evolution of GLP rules to better address new challenges in research and regulatory compliance. Facilities must remain vigilant and committed to maintaining GLP standards, ensuring that the safety data they produce continues to support and guide critical decisions in public health. By adhering to these principles, laboratories not only fulfill regulatory requirements but also contribute to advancing trust in scientific findings globally.

References

July 29, 2026
Compounded medications are a routine part of modern care, but unlike mass-manufactured drugs, each one is prepared individually, which means the standards behind its preparation carry real weight. For providers who order or refer for compounded therapies, a working understanding of those standards is the clearest way to judge whether a pharmacy is safe to trust. This overview covers the standards that govern sterile compounding and what they mean for the medications your patients receive. Why Standards Matter More in Compounding A commercially manufactured drug is produced under FDA oversight in large, validated batches. A compounded medication is prepared for an individual patient, often in small quantities, sometimes because no commercial equivalent exists. That flexibility is exactly why it's clinically valuable — and why the standards around preparation exist. Without rigorous controls, the same customization that helps patients could introduce contamination or error. Our guide to our sterile compounding pharmacy describes how those controls come together in practice. The Regulatory Landscape Sterile compounding sits within a layered framework: The United States Pharmacopeia (USP) publishes the general chapters, most importantly <797> and <800>, that define how compounded preparations should be made and handled. State boards of pharmacy license and inspect pharmacies, including where they're permitted to ship. Multi-state operations must maintain licensure in each state they serve. Accreditation bodies (ACHC, NABP, PCAB) provide independent verification that a pharmacy meets recognized standards. Together, these create the accountability structure behind every compounded dose. USP <797>: Sterile Preparations USP <797> is the cornerstone standard for compounded sterile preparations. It governs the conditions and practices required to keep a preparation free of contamination, including personnel training and garbing, ISO-classified air quality and engineering controls, environmental monitoring, and beyond-use dating. For any medication infused directly into the body, <797> compliance is the baseline expectation, not a premium feature. USP <800>: Hazardous Drugs USP <800> adds a containment layer for hazardous drugs, protecting personnel, patients, and the environment from unintended exposure. It specifies containment engineering controls, PPE, and validated handling procedures for drugs identified as hazardous. When a preparation is both sterile and hazardous, it must satisfy <797> and <800> together. For the details, see our breakdown of USP <800> requirements . Accreditation: Independent Verification Standards are only meaningful if someone checks that they're being met. Accreditation from ACHC, NABP, and PCAB means a pharmacy has been inspected against national benchmarks by an outside authority. For a provider, accreditation is a shortcut to confidence: it signals that the pharmacy's claims about its processes have been independently validated. The Quality-Control Process Behind the standards is a repeatable process that governs each preparation: Pharmacist review of the prescription for appropriateness, compatibility, and dosing Preparation by trained technicians under aseptic conditions In-process and final verification by a licensed pharmacist Sterility testing or filtration validation where required This chain is what turns a standard on paper into a safe medication in a patient's hands. What This Means When You Order When you refer a patient for a compounded therapy, you're effectively extending your own standard of care into another facility. Knowing that a pharmacy is USP-compliant, accredited, and pharmacist-led lets you refer with confidence that the medication will meet the same expectations you'd hold for anything you administer yourself. If you're weighing options, our guide on how to choose a compounding partner walks through the criteria. The Pharmko Standard Pharmko compounds every TPN, IDPN, and IPN preparation in a USP <797>-compliant, ISO Class 5 cleanroom, under ACHC, NABP, and PCAB accreditation, with a licensed pharmacist reviewing and releasing each formula. For the patients who receive our preparations, many of them managing End Stage Renal Disease (ESRD), that standard is the point. Refer a Patient → · [1 (877) 540-2003]
Physician evaluating a sterile compounding pharmacy partner
July 29, 2026
How to evaluate a sterile compounding pharmacy: accreditation, USP compliance, clinical support, turnaround, and the questions every practice should ask.
Sterile compounding pharmacy technician in PPE under a containment hood
July 29, 2026
A clear guide to USP 800 requirements: hazardous drug handling, containment, PPE, and the facility standards every sterile compounding pharmacy must meet.
Myasthenia Gravis and IVIG: What Patients Need to Know About IV Therapy
July 20, 2026
Learn how IVIG therapy works for myasthenia gravis, when it's used, what to expect during infusions, how home IVIG is coordinated, and how Pharmko supports MG patients and their neurologists.
Dobutamine and Inotrope Therapy at Home
July 17, 2026
Learn how home dobutamine infusion works for advanced heart failure, who qualifies, how continuous inotrope therapy is managed at home, and how Pharmko supports cardiac patients and heart failure teams.
CIDP and Home Infusion: IVIG Treatment, Dosing Schedule, and Long-Term Management
July 16, 2026
Learn how IVIG therapy works for CIDP, what the dosing schedule looks like, how to transition to home infusion, and how Pharmko supports long-term CIDP management across 22+ states.
Compounded IV Medications
July 15, 2026
Most medications that patients receive at a hospital or pharmacy come in standardized, commercially manufactured forms, a 500mg antibiotic vial, a pre-filled syringe, a fixed-concentration IV bag. These products work well for many patients. But a significant portion of patients receiving IV therapy have clinical needs that commercial products cannot meet: a dose the manufacturer doesn't make, a formulation incompatible with the patient's allergy profile, or a combination of nutrients that must be tailored to individual lab values. For these patients, compounded IV medications are not optional, they are clinically necessary. Pharmko's sterile compounding services prepare customized IV medications for patients across 22+ states, with every formulation reviewed by a licensed pharmacist and prepared in a USP <797> compliant cleanroom. What Makes an IV Medication 'Compounded'? A compounded medication is one that is prepared specifically for an individual patient by a licensed pharmacist, rather than manufactured in bulk by a pharmaceutical company. Compounding involves combining, mixing, or altering ingredients, active pharmaceutical ingredients, diluents, preservatives, to create a final preparation that meets the patient's unique prescription requirements. For IV therapy specifically, compounding means preparing a sterile preparation, one that is completely free of viable microorganisms and safe to inject or infuse directly into the bloodstream. This requires specialized facilities, equipment, training, and quality systems that go far beyond what a standard retail pharmacy can provide. Pharmko is exclusively a sterile compounding pharmacy. We do not compound oral medications, topical creams, or non-sterile preparations. Every product we make is intended for intravenous, intraperitoneal, or subcutaneous administration. When Are Compounded IV Medications Necessary? The required dose doesn't exist commercially Pharmaceutical manufacturers produce medications in standardized strengths and volumes based on average patient needs. Pediatric patients, patients with renal or hepatic impairment requiring dose adjustments, or patients whose weight or clinical status falls outside standard ranges may need concentrations or volumes that no commercial product provides. Compounding fills this gap precisely. The patient has an allergy to a commercial formulation's inactive ingredients Commercial IV products often contain preservatives, stabilizers, or diluents, sulfites, benzyl alcohol, certain dyes, that some patients cannot tolerate. A compounding pharmacy can prepare an equivalent formulation without the offending ingredient, allowing the patient to receive the therapy safely. The medication requires individualized nutrient formulation Total parenteral nutrition (TPN) is the clearest example: every TPN formula must be individually compounded because no commercial product can provide the precise combination of amino acids, dextrose, lipids, electrolytes, vitamins, and trace minerals a specific patient needs. The formula changes as the patient's labs, weight, and clinical status change, making standardization impossible. The commercial product is unavailable or in shortage Drug shortages are a persistent reality in the US pharmaceutical supply chain. When a commercially manufactured IV medication becomes unavailable, compounding pharmacies can often prepare an equivalent formulation from available active pharmaceutical ingredients, bridging the gap and maintaining continuity of therapy for patients who cannot wait. The therapy requires a custom delivery format Some IV medications require specific pH, osmolarity, or concentration adjustments for compatibility with a patient's IV access device or concurrent medications. A compounding pharmacist reviews compatibility and prepares formulations that are safe and stable for the specific administration route and equipment the patient is using. How Compounded IV Medications Are Made Step 1: Prescription review Every compounded IV medication begins with a valid prescription from a licensed prescriber. Pharmko's pharmacists review the prescription for clinical appropriateness, dosing accuracy, ingredient compatibility, and stability before compounding begins. Step 2: Ingredient sourcing and verification Active pharmaceutical ingredients for compounding must come from FDA-registered suppliers and meet USP monograph specifications. Each lot is verified for identity, potency, and purity before use. Step 3: Sterile preparation in a controlled environment Preparation occurs in an ISO Class 5 laminar airflow workbench or biological safety cabinet, located within a buffer room that meets ISO Class 7 air quality standards. Pharmacy technicians follow validated, written procedures for each preparation type, using aseptic technique to prevent contamination at every step. Step 4: Pharmacist verification and release A licensed pharmacist performs a final check of every preparation, verifying appearance, volume, labeling, and documentation, before the product is released. High-risk or complex preparations may undergo sterility testing with defined beyond-use dates based on test results. Step 5: Cold-chain delivery Most compounded IV medications require refrigeration. Pharmko uses validated cold-chain packaging and delivery logistics to ensure products arrive within their stability windows and remain temperature-controlled until the patient uses them. Quality Standards That Matter Not all compounding pharmacies operate at the same standard. The relevant quality benchmarks for sterile compounding are: USP <797> compliance, the national standard for sterile compounding environments, personnel, and processes. Our guide on USP <797> and USP <800> explains what compliance means in practice ACHC accreditation, independent third-party verification that Pharmko meets clinical quality standards for home infusion and sterile compounding State pharmacy board licensure, Pharmko is licensed in every state where we serve patients Environmental and personnel monitoring, documented air and surface sampling, personnel gowning competency assessments, and media fill testing at defined intervals For a foundational overview of what sterile compounding is and how it differs from retail pharmacy, see our guide on what is sterile compounding for IV therapy . → Contact Pharmko about compounded IV medications: 1-877-540-2003
home infusion therapy Pennsylvania
July 14, 2026
Pharmko provides home infusion therapy across Pennsylvania, IV antibiotics, IVIG, TPN, biologics, and specialty medications. Licensed, ACHC accredited, and available 24/7 statewide.
Home Infusion Therapy in New Jersey
July 14, 2026
Pharmko provides home infusion therapy across New Jersey, IV antibiotics, IVIG, TPN, IDPN, biologics, and more. Licensed, ACHC accredited, and available 24/7 statewide.
Renal dietitian reviewing albumin labs for a peritoneal dialysis patient
July 10, 2026
When to consider IPN for peritoneal dialysis patients with low albumin: clinical criteria, the stepwise nutrition approach, and the referral process.
Show More